Skip to main content

BRIEF-Glaxosmithkline Submits Regulatory Application For Single-Dose Tafenoquine For Treatment Of Plasmodium Vivax Malaria

* SUBMITS REGULATORY APPLICATION FOR SINGLE-DOSE TAFENOQUINE FOR TREATMENT OF PLASMODIUM VIVAX MALARIA TO AUSTRALIA'S THERAPEUTIC GOODS ADMINISTRATION​
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.